|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
1982
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AB01
|
|
gptkbp:bioavailability_(oral)
|
10–20%
|
|
gptkbp:brand
|
gptkb:Sitavig
gptkb:Zovirax
gptkb:Acic
|
|
gptkbp:CASNumber
|
59277-89-3
|
|
gptkbp:category
|
antiviral drug
purine analogue
|
|
gptkbp:chemicalFormula
|
C8H11N5O3
|
|
gptkbp:contraindication
|
hypersensitivity to aciclovir
hypersensitivity to valaciclovir
|
|
gptkbp:developedBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discoveredBy
|
gptkb:Howard_Schaeffer
1974
|
|
gptkbp:drugbank_id
|
gptkb:DB00787
|
|
gptkbp:eliminationHalfLife
|
2–3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:first_marketed
|
1981
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aciclovir
|
|
gptkbp:IUPACName
|
2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one
|
|
gptkbp:legal_status_(UK)
|
prescription only
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA polymerase
|
|
gptkbp:meltingPoint
|
256–257 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
225.21 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:pubchem_cid
|
2022
|
|
gptkbp:relatedTo
|
gptkb:famciclovir
gptkb:ganciclovir
gptkb:valaciclovir
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
headache
renal dysfunction
|
|
gptkbp:synonym
|
gptkb:acyclovir
|
|
gptkbp:usedFor
|
herpes simplex virus infection
herpes zoster
varicella zoster virus infection
herpes labialis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:acyclovir
|
|
gptkbp:bfsLayer
|
6
|